Providers believe the digital modality could ultimately provide a more accurate cancer diagnosis compared to conventional PET, authors reported in the Journal of Nuclear Medicine.
The U.S Food and Drug Administration gave the go-ahead for two additional molybdenum-99 filling lines at the company's Columbia, Missouri, facility.
A generative adversarial network accurately segmented brain white matter volume by analyzing hundreds of patient images, researchers reported in the Journal of Digital Imaging.
Idaho-based International Isotopes has received U.S. Food and Drug Administration approval for its radioactive therapeutic agent used to treat thyroid cancers.
Randall Batemen, MD, principal investigator of the research and a neurologist at Washington University in St. Louis, told the New York Times the results were "really crushing."
The National Institute on Aging awarded Wake Forest School of Medicine a five-year grant to examine if a novel PET tracer can help researchers tackle the disease.
Nuclear medicine experts called on the field to work together and share data in order to produce the sample sizes needed for further breakthroughs.
The imaging agent—Myeliviz—will be tested in humans for the first time, and may change the way clinicians diagnose the autoimmune disease.
The approach can help families make more informed treatment decisions, which can be critical for organ donation, according to authors of a new study.
Imaging markers such as breast parenchymal uptake varied greatly between women with benign and malignant lesions, according to a study published in the Journal of Nuclear Medicine.
The findings may offer new targets for researching and treating patients with the condition.
The move delays a restriction on licenses required to export highly enriched uranium for two years.